Drug Trial Radar · NCT01525602
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jul 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
May 2012
Primary completion
Dec 2017
Study completion Feb 2018
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Plexxikon
- First posted
- Feb 3, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a 3-part study designed to explore the safety and tolerability of escalating doses of PLX3397 with weekly paclitaxel to establish a recommended Phase 2 dose (RP2D), to confirm RP2D in participants with advanced non-resectable solid tumors, and to determine the efficacy of PLX3397 600 mg twice daily (BID) administered in combination with weekly paclitaxel in participants with advanced, metastatic or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Conditions
- Solid Tumors
Interventions
PLX3397Drug
PLX3397 tablets, 200mg
PaclitaxelDrug
Paclitaxel IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-emergent Adverse Events (>10%) Classified by Preferred Term Following PLX3397 Administered in Combination With Paclitaxel (Parts 1 and 2) (Safety Population)Time frame: From post first dose up to 28 days after the last dose, up to 5 years 9 months
- Percentage of Participants With TEAEs (>10%) Classified by Preferred Term Following PLX3397 Administered in Combination With Paclitaxel (Part 3) (Safety Population)Time frame: From post first dose up to 28 days after the last dose, up to 5 years 9 months
- Best Overall Tumor Response Based on RECIST V1.1 Following PLX3397 Administered in Combination With Paclitaxel (Parts 1 and 2) (Efficacy Evaluable Population)Time frame: From post first dose up to 5 years 9 months post dose
- Best Overall Tumor Response Based on RECIST V1.1 Following PLX3397 Administered in Combination With Paclitaxel (Part 3) (Efficacy Evaluable Population)Time frame: From 26 days (CR and PR) and 54 days (SD) up to 5 years 9 months post dose
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Univeristy of California, San Francisco
San Francisco, California
University of Colorado, Anschutz Cancer Pavilion
Aurora, Colorado
Sylvester Comprehensive Cancer Center/UMHC
Miami, Florida
Mayo Clinic
Rochester, Minnesota
University Hospitals of Cleveland
Cleveland, Ohio
Ohio State University
Columbus, Ohio
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.